Identifying the association of contrast enhancement with vascular endothelia growth factor expression in anaplastic gliomas: A volumetric magnetic resonance imaging analysis

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Wang, Yinyan ^a,b   Wang, Kai ^b   Li, Hongming ^c   Wang, Jiangfei ^b   Wang, Lei ^b   Dai, Jianping ^b   Jiang, Tao ^a,b,d   Ma, Jun ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^d BEIJING INSTITUTE FOR BRAIN DISORDERS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER; VASCULOTROPIN; CONTRAST MEDIUM; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ANAPLASTIC CARCINOMA; ANAPLASTIC GLIOMA; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; FEMALE; GLIOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PREOPERATIVE EVALUATION; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SURVIVAL RATE; TUMOR NECROSIS; UPREGULATION; VOLUMETRY; ADOLESCENT; BRAIN NEOPLASMS; IMAGE ENHANCEMENT; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL ANALYSIS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; CONTRAST MEDIA; FEMALE; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROGNOSIS; RADIOGRAPHIC IMAGE ENHANCEMENT; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 84926344354     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0121380     Document Type: Article

References (38)

1. DeAngelis LM. Anaplastic glioma: how to prognosticate outcome and choose a treatment strategy. [corrected]. J Clin Oncol. 2009; 27: 5861-5862. doi: 10.1200/JCO.2009.24.5985 PMID: 19901101
2. Lin CL, Lieu AS, Lee KS, Yang YH, Kuo TH, Hung MH, et al. The conditional probabilities of survival in patients with anaplastic astrocytoma or glioblastoma multiforme. Surg Neurol. 2003; 60: 402-406; discussion 406. PMID: 14572960
3. Lin N, Yan W, Gao K, Wang Y, Zhang J, You Y. Prevalence and clinicopathologic characteristics of the molecular subtypes in malignant glioma: a multi-institutional analysis of 941 cases. PLoS One. 2014; 9: e94871. doi: 10.1371/journal.pone.0094871 PMID: 24755548
4. Tortosa A, Vinolas N, Villa S, Verger E, Gil JM, Brell M, et al. Prognostic implication of clinical, radiologic, and pathologic features in patients with anaplastic gliomas. Cancer. 2003; 97: 1063-1071. PMID: 12569607
5. Beiko J, Suki D, Hess KR, Fox BD, Cheung V, Cabral M, et al. IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro Oncol. 2014; 16: 81-91. doi: 10.1093/neuonc/not159 PMID: 24305719
6. Lin Y, Chen Y, Wang Y, Yang J, Zhu VF, Liu Y, et al. ZIP4 is a novel molecular marker for glioma. Neuro Oncol. 2013; 15: 1008-1016. doi: 10.1093/neuonc/not042 PMID: 23595627
7. Tomita T, Akimoto J, Haraoka J, Kudo M. Clinicopathological significance of expression of nestin, a neural stem/progenitor cell marker, in human glioma tissue. Brain Tumor Pathol. 2013.
8. Burel-Vandenbos F, Turchi L, Benchetrit M, Fontas E, Pedeutour Z, Rigau V, et al. Cells with intense EGFR staining and a high nuclear to cytoplasmic ratio are specific for infiltrative glioma: a useful marker in neuropathological practice. Neuro Oncol. 2013; 15: 1278-1288. doi: 10.1093/neuonc/not094 PMID: 23935154
9. Flamme I, Frolich T, Risau W. Molecular mechanisms of vasculogenesis and embryonic angiogenesis. J Cell Physiol. 1997; 173: 206-210. PMID: 9365523
10. Inoue H, Aihara M, Tomioka M, Watabe Y. Specific enhancement of vascular endothelial growth factor (VEGF) production in ischemic region by alprostadil - potential therapeutic application in pharmaceutical regenerative medicine. J Pharmacol Sci. 2013; 122: 158-161. PMID: 23728380
11. Inoue K, Torimura T, Nakamura T, Iwamoto H, Masuda H, Abe M, et al. Vandetanib, an inhibitor of VEGF receptor-2 and EGF receptor, suppresses tumor development and improves prognosis of liver cancer in mice. Clin Cancer Res. 2012; 18: 3924-3933. doi: 10.1158/1078-0432.CCR-11-2041 PMID: 22611027
12. Lu X, Gu Y, Ding Y, Song W, Mao J, Tan J, et al. Correlation of ER, PgR, HER-2/neu, p53, and VEGF with clinical characteristics and prognosis in Chinese women with invasive breast cancer. Breast J. 2008; 14: 308-310. doi: 10.1111/j.1524-4741.2008.00583.x PMID: 18476890
13. Zhang SJ, Hu Y, Qian HL, Jiao SC, Liu ZF, Tao HT, et al. Expression and significance of ER, PR, VEGF, CA15-3, CA125 and CEA in judging the prognosis of breast cancer. Asian Pac J Cancer Prev. 2013; 14: 3937-3940. PMID: 23886210
14. Chen J, Tang D, Wang S, Li QG, Zhang JR, Li P, et al. High expressions of galectin-1 and VEGF are associated with poor prognosis in gastric cancer patients. Tumour Biol. 2014; 35: 2513-2519. doi: 10.1007/s13277-013-1332-8 PMID: 24241899
15. Vidal O, Soriano-Izquierdo A, Pera M, Elizalde JI, Palacin A, Castells A, et al. Positive VEGF immunostaining independently predicts poor prognosis in curatively resected gastric cancer patients: results of a study assessing a panel of angiogenic markers. J Gastrointest Surg. 2008; 12: 1005-1014. PMID: 17972143
16. Vogelbaum MA, Jost S, Aghi MK, Heimberger AB, Sampson JH, Wen PY, et al. Application of novel response/ progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery. 2012; 70: 234-243; discussion 243-234. doi:10.1227/NEU.0b013e318223f5a7 PMID: 21593697
17. Carrillo JA, Lai A, Nghiemphu PL, Kim HJ, Phillips HS, Kharbanda S, et al. Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma. AJNR Am J Neuroradiol. 2012; 33: 1349-1355. doi: 10.3174/ajnr.A2950 PMID: 22322613
18. Qi S, Yu L, Li H, Ou Y, Qiu X, Ding Y, et al. Isocitrate dehydrogenase mutation is associated with tumor location and magnetic resonance imaging characteristics in astrocytic neoplasms. Oncol Lett. 2014; 7: 1895-1902. PMID: 24932255
19. Kim JW, Park CK, Park SH, Kim YH, Han JH, Kim CY, et al. Relationship between radiological characteristics and combined 1p and 19q deletion in World Health Organization grade III oligodendroglial tumours. J Neurol Neurosurg Psychiatry. 2011; 82: 224-227. doi: 10.1136/jnnp.2009.178806 PMID: 20587495
20. Lote K, Egeland T, Hager B, Skullerud K, Hirschberg H. Prognostic significance of CT contrast enhancement within histological subgroups of intracranial glioma. J Neurooncol. 1998; 40: 161-170. PMID: 9892098
21. Conway AE, Reddick WE, Li Y, Yuan Y, Glass JO, Baker JN, et al. "Occult" post-contrast signal enhancement in pediatric diffuse intrinsic pontine glioma is the MRI marker of angiogenesis? Neuroradiology. 2014; 56: 405-412. doi: 10.1007/s00234-014-1348-9 PMID: 24626721
22. Su MY, Cheung YC, Fruehauf JP, Yu H, Nalcioglu O, Mechetner E, et al. Correlation of dynamic contrast enhancement MRI parameters with microvessel density and VEGF for assessment of angiogenesis in breast cancer. J Magn Reson Imaging. 2003; 18: 467-477. PMID: 14508784
23. Kwak BK, Shim HJ, Park US, Lee TJ, Paeng SS, Lee CJ, et al. Correlation of VEGF with contrast enhancement on dual-phase dynamic helical CT in liver tumors: preliminary study. J Korean Med Sci. 2001; 16: 83-87. PMID: 11289406
24. Wei X, Li Y, Zhang S, Ming G. Evaluation of thyroid cancer in Chinese females with breast cancer by vascular endothelial growth factor (VEGF), microvessel density, and contrast-enhanced ultrasound (CEUS). Tumour Biol. 2014; 35: 6521-6529. doi: 10.1007/s13277-014-1868-2 PMID: 24687553
25. Liu X, Zhang H, Yu X, Song T, Huang P, Wang H, et al. The correlation of expression of VEGF and EGFR with SUV of (18)FDG-PET-CT in non-small cell lung cancer. Contemp Oncol (Pozn). 2014; 18: 334-339. doi: 10.5114/wo.2014.45308 PMID: 25477756
26. Liu J, Xiong Z, Zhou H, Zhou M, Zhou J, Fu C. [Multi-slice spiral CT pulmonary perfusion imaging and the expression of VEGF/PCNA in non-small cell lung cancer]. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2009; 34: 406-411. PMID: 19483288
27. Shweiki D, Neeman M, Itin A, Keshet E. Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis. Proc Natl Acad Sci U S A. 1995; 92: 768-772. PMID: 7531342
28. Hong HS, Kim SH, Park HJ, Park MS, Kim KW, Kim WH, et al. Correlations of dynamic contrast-enhanced magnetic resonance imaging with morphologic, angiogenic, and molecular prognostic factors in rectal cancer. Yonsei Med J. 2013; 54: 123-130. doi: 10.3349/ymj.2013.54.1.123 PMID: 23225808
29. Jensen RL, Mumert ML, Gillespie DL, Kinney AY, Schabel MC, Salzman KL. Preoperative dynamic contrast-enhanced MRI correlates with molecular markers of hypoxia and vascularity in specific areas of intratumoral microenvironment and is predictive of patient outcome. Neuro Oncol. 2014; 16: 280-291. doi: 10.1093/neuonc/not148 PMID: 24305704
30. Talasila KM, Soentgerath A, Euskirchen P, Rosland GV, Wang J, Huszthy PC, et al. EGFR wild-type amplification and activation promote invasion and development of glioblastoma independent of angiogenesis. Acta Neuropathol. 2013; 125: 683-698. doi: 10.1007/s00401-013-1101-1 PMID: 23429996
31. Roberts WG, Palade GE. Neovasculature induced by vascular endothelial growth factor is fenestrated. Cancer Res. 1997; 57: 765-772. PMID: 9044858
32. Esser S, Wolburg K, Wolburg H, Breier G, Kurzchalia T, Risau W. Vascular endothelial growth factor induces endothelial fenestrations in vitro. J Cell Biol. 1998; 140: 947-959. PMID: 9472045
33. Winger MJ, Macdonald DR, Cairncross JG. Supratentorial anaplastic gliomas in adults. The prognostic importance of extent of resection and prior low-grade glioma. J Neurosurg. 1989; 71: 487-493. PMID: 2552044
34. Donahue B, Scott CB, Nelson JS, Rotman M, Murray KJ, Nelson DF, et al. Influence of an oligodendroglial component on the survival of patients with anaplastic astrocytomas: a report of Radiation Therapy Oncology Group 83-02. Int J Radiat Oncol Biol Phys. 1997; 38: 911-914. PMID: 9276354
35. Ino Y, Zlatescu MC, Sasaki H, Macdonald DR, Stemmer-Rachamimov AO, Jhung S, et al. Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss. J Neurosurg. 2000; 92: 983-990. PMID: 10839259
36. Shaw EG, Scheithauer BW, O'Fallon JR, Davis DH. Mixed oligoastrocytomas: a survival and prognostic factor analysis. Neurosurgery. 1994; 34: 577-582; discussion 582. PMID: 8008153
37. Nam DH, Park K, Suh YL, Kim JH. Expression of VEGF and brain specific angiogenesis inhibitor-1 in glioblastoma: prognostic significance. Oncol Rep. 2004; 11: 863-869. PMID: 15010886
38. Sjostrom S, Wibom C, Andersson U, Brannstrom T, Broholm H, Johansen C, et al. Genetic variations in VEGF and VEGFR2 and glioblastoma outcome. J Neurooncol. 2011; 104: 523-527. doi: 10.1007/s11060-010-0504-2 PMID: 21191630